An interventional study of Vorasidenib in Gliomas, sponsored by Servier (Tianjin) Pharmaceutical Co. LTD.. Active, not recruiting at 3 sites in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Servier (Tianjin) Pharmaceutical Co. LTD. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 162 studies in Glioma with a site in China — 70 open to participants now, 82 under way, 3 of them phase 3. Glioma · China.
Among the 162 studies in Glioma with a site in China, this one is the 34th largest by enrollment of the 112 interventional ones that give a count, is one of 16 that started in 2025, is one of 36 with no phase, reaches primary completion later than 68 of the 81 other live ones, and was the 133rd registered.
1,453 studies on the registry are indexed under Glioma; 349 are open to participants now.
Browse Glioma studies →70 of the 162 studies in Glioma with a site in China are open now. Recruiting first, the newest first:
Beijing Inno Medicine Co., Ltd. · Sites in China, United States
Ages 18–70
Neuregen Therapeutics Co., Ltd. · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
HighField Biopharmaceuticals Corporation · Sites in China
Ages 18–75
Xiangya Hospital of Central South University · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 267 Glioma studies recruiting now, 164 (61%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
162 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 33 · Phase 3 6 · Phase 4 1
First in 2006; this study’s year is marked. 16 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is above the median of 32 across 1,075 interventional studies indexed under Glioma.
Median enrollment 40 across the 112 interventional studies, 345 across the 50 observational. Of the 22 that completed or were terminated, 2 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 162 have an industry lead sponsor. The 10 most frequent:
Servier (Tianjin) Pharmaceutical Co. LTD. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Servier (Tianjin) Pharmaceutical Co. LTD. has 1 study filed under Glioma — fewer than ten, so there is no comparison to draw.
27 of the studies in Glioma with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06330337Phase 3The Third Affiliated hospital of Zhejiang Chinese Medical UniversityEffect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma | 2026-12-31 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT07940231Beijing Tiantan HospitalProspective Study of Intraoperative Brain Tumor Photographs for Pathological and Molecular Classification | 2026-11-30 |
| NCT06368934Huashan HospitalSub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma | 2026-12 |
| NCT04794972Sichuan Baili Pharmaceutical Co., Ltd.A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors | 2026-12 |
Add all 27 to your calendar (.ics) → With an account.
Among the 162 studies in Glioma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this Study is to evaluate the effectiveness and safety of Vorasidenib in Patients with Isocitrate dehydrogenase IDH1/2 mutant Grade 2 astrocytoma or oligodendroglioma, primary purposeis to evaluate the efficectiveness of Vorasidenib in glioma patients treated in routine clinical practice in In China, patients aged 12 and above with grade II or higher astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations. The main question it aims to answer is:
if this trend is consistent with the efficacy observed in the INDIGO study, and there is not any new safety signal compared to previous research data? Researchers will compare to no treatment. Participants is not mandatory for a formal visit as it is a real-word study.However, due to the fact that patients will be treated with new drugs and need to collect data on major efficacy, regular visits should be performed in routine clinical practice.
This study is a multicenter, retrospective-and prospective real-world study, There are treatment group (Vorasidenib) and external control group (untreated after surgery).
Inclusion and exclusion criteria for treatment group
Patients will be included if they meet all the following criteria:
Patients who meet at least one of the following exclusion criteria will not be included in the study:
Inclusion and exclusion criteria for the external control group
Patients will be included if they meet all the following criteria:
6) Must have at least 6 months (±30 days) follow-up historical data since the index date without any treatment in this period.
Patients who meet at least one of the following exclusion criteria will not be included in the study:
1) Patients who received radiotherapy, chemotherapy or other IDH inhibitors for Glioma before the index date.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
As a real-world study, in principle, a formal visit is not mandatory. However, due to the fact that patients will be treated with new drugs and need to collect data on major efficacy, regular visits should be performed in routine clinical practice.
Drug: Vorasidenib
Eligible patients are those who have MRI data available for analysis after glioma surgery (including biopsy, subtotal resection, or total resection) and at least one additional MRI scan available for analysis within the following 6 months after the index data During this period, the eligible patients who have not undergone radiotherapy or chemotherapy after resection will be included in the external control arm.
Treatment group: recommended dosage in adults and paediatric patients 12 years of age and older: * For patients weighing at least 40 kg: 40 mg, orally, once daily. * For patients weighing less than 40 kg: 20 mg, orally, once daily.
Primary efficacy endpoint
TGR at 6 months after the index date\*. TGR is defined as percentage change in tumour volume from baseline.
Time frame: at 6 months after the index date
Secondary efficacy endpoint
TTNI, TTNI is defined as the time from enrolment to the initiation of the first subsequent anticancer therapy or death due to any causes whichever occurs earlier.
Time frame: 30 months after the index date of the last required sample patient
Secondary efficacy endpoint
rwPFS, defined as the time from enrolment to physician-documented disease progression or date of death due to any cause, whichever occurs earlier, evaluated according to the modified RANO-LGG.
Time frame: 30 months after the index date of the last required sample patient
Secondary efficacy endpoint
TGR every 6 months after the index date, defined as the percentage change in tumor volume every 6 months after the index date in the Vorasidenib treatment group, as assessed per IRC.
Time frame: 30 months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Apr 2028, 31 months after the start.
Of 142 interventional studies with no phase under Glioma, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 114. This study's planned 31 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorasidenib
Servier (Tianjin) Pharmaceutical Co. LTD.